Mosaic neurofibromatosis type 1

Advocacy intelligence hub — real-time data for patient organizations

View full disease page →Search clinical trials →
Download CSV

At a Glance

Live from database

Regulatory Watchboard

No FDA or trial events recorded yet for Mosaic neurofibromatosis type 1.

Financial Assistance

1 program

FINANCIAL LANDSCAPE SUMMARY

1

Total programs

1

Open now

Patient Assistance Programs1

Koselugo

AstraZeneca / Alexion

OpenContact for detailsApply ↗

View all support programs on disease page →

Approved Treatments

1 FDA-approved

Koselugo

(selumetinib)Orphan drug

AstraZeneca / Alexion

Kinase Inhibitor [EPC]

12.1 Mechanism of Action Selumetinib is an inhibitor of mitogen-activated protein kinase kinases 1 and 2 (MEK1/2). MEK1/2 proteins are upstream regula...

Approved Nov 2025FDA label ↗

View full treatment details on disease page →

Clinical Trial Landscape

No active clinical trials currently recruiting for Mosaic neurofibromatosis type 1.
Search all trials →
Search clinical trials for Mosaic neurofibromatosis type 1

Recent News & Research

No recent news articles indexed yet for Mosaic neurofibromatosis type 1.
Search PubMed for Mosaic neurofibromatosis type 1

Browse all Mosaic neurofibromatosis type 1 news →

Specialist Network

Top 1 by expertise

View all Mosaic neurofibromatosis type 1 specialists →

Quick Actions